Supreme Court Directs Baba Ramdev and Patanjali MD to Appear in Person
National Desk, 19th March: The Supreme Court, on March 19, issued a directive for Yoga guru Baba Ramdev and Patanjali Ayurved’s Managing Director Acharya Balkrishna to appear in person within two weeks concerning the company’s alleged dissemination of misleading advertisements.
Background of the Case:
This decision follows the Court’s previous restraint on Patanjali Ayurved from publishing advertisements for various ailments, including blood pressure, diabetes, arthritis, asthma, and obesity, on February 27.
Contempt Notice and Petition by IMA:
The contempt notice against Patanjali Ayurved and Acharya Balkrishna stemmed from a petition filed by the Indian Medical Association (IMA). During the hearing, the bench, comprising Justices Hima Kohli and Amanullah, expressed dissatisfaction over the lack of a response despite prior directives.
Concerns Over Violation of Drugs and Magic Remedies Act:
Justice Kohli highlighted the possibility of contempt proceedings against Baba Ramdev, considering the Court’s prima facie opinion of his violation of the Drugs and Magic Remedies Act. Senior Advocate Mukul Rohatgi, representing Baba Ramdev, faced queries from the bench regarding the delayed response to the contempt notice.
Rejection of Plea and Criticism of Union Ayush Ministry:
The Court rejected Rohatgi’s plea to exclude Baba Ramdev from the case, emphasizing his significant presence in Patanjali’s advertisements and press conferences. Additionally, criticism was directed towards the Union Ayush Ministry for filing its response just a day before the hearing. The Ministry requested additional time to submit a comprehensive affidavit, which the Court granted.
Disclosure by Centre Regarding Misleading Advertisements:
Previously, the Centre disclosed in its affidavit that it had received 35,556 complaints regarding misleading advertisements against various companies. It further stated that the Ayush Ministry had issued a notice to Patanjali Ayurved concerning its claim of developing a COVID-19 cure named CORONIL, based on representations received.